Sex Differences in the Clinical Manifestations of Alzheimer Disease Pathology
2005/06/01 by Lisa L. Barnes, Robert S. Wilson, Julia L. Bienias +3 · 36 citations
Medicine · #Dementia and Cognitive Impairment Research #Alzheimer's disease research and treatments #Schizophrenia research and treatment
paper · doi:10.1001/archpsyc.62.6.685
Abstract
CONTEXT: Sex differences in risk of clinically diagnosed Alzheimer disease (AD) have been studied extensively, but little is known about the relation of the pathologic indices of AD to the clinical manifestations of the disease in men compared with women. OBJECTIVE: To test whether the relation of AD pathology to the clinical manifestations of the disease differs in men and women. DESIGN: Longitudinal, clinicopathologic cohort study. PARTICIPANTS AND SETTING: Analyses were conducted on 141 older Catholic clergy members who underwent detailed annual clinical evaluations and brain autopsy at death. The number of neuritic plaques, diffuse plaques, and neurofibrillary tangles in a 1-mm2 area sampled from 4 cortical regions was counted, and a global measure of AD pathology (range, 0-2.98 U) and specific measures of each pathology were derived. MAIN OUTCOME MEASURES: Clinical diagnosis of probable AD and level of global cognitive function at the last evaluation before death. RESULTS: Women had more global AD pathology than did men (P = .04), due primarily to more neurofibrillary tangles (P = .02). At the last evaluation before death, 57 persons met clinical criteria for probable AD (34 [60%] of them women). In logistic regression models, sex was not related to odds of clinical AD (odds ratio [OR], 1.35; 95% confidence interval [CI], 0.56-3.25), but the relation of global AD pathology to clinical diagnosis differed for men and women. Each additional unit of AD pathology was associated with a nearly 3-fold increase in the odds of clinical AD in men (OR, 2.82; 95% CI, 1.03-7.65) compared with a more than 20-fold increase in the odds of clinical AD in women (OR, 22.67; 95% CI, 5.11-100.53). Results were unchanged after controlling for potential confounders or using level of cognition as the outcome. CONCLUSION: These data suggest that AD pathology is more likely to be clinically expressed as dementia in women than in men.
Citations
Cited by
- Gender Differences in Alzheimer Disease: Brain Atrophy, Histopathology Burden, and Cognition
- Daniel Cosío Villegas: una biografía intelectual
- Protective actions of sex steroid hormones in Alzheimer’s disease
- Women’s midlife: the front line of Alzheimer prevention
- The connection between autophagy and Alzheimer’s disease
- Deep learning reveals pathology-confirmed neuroimaging signatures in Alzheimer’s, vascular and Lewy body dementias
- Sex Mediates Relationships Between Regional Tau Pathology and Cognitive Decline
- Tri-AD: Hippocampal cell-type-specific responses to age, sex and APOE genotype
- Exploring the parity paradox: Differential effects on neuroplasticity and inflammation by APOEe4 genotype at middle age
- Sexually Dimorphic Expression of Reelin in the Brain of a Mouse Model of Alzheimer Disease
- Neuroimmunology and neuroepigenetics in the establishment of sex differences in the brain
- Sex and the development of Alzheimer's disease
- Age-dependent sexual dimorphism in cognition and stress response in the 3xTg-AD mice. [europepmc]
- Protective actions of sex steroid hormones in Alzheimer's disease. [europepmc]
- Sex differences in β-amyloid accumulation in 3xTg-AD mice: role of neonatal sex steroid hormone exposure. [europepmc]
- Altered default mode network connectivity in Alzheimer's disease--a resting functional MRI and Bayesian network study. [europepmc]
- Overview and findings from the religious orders study. [europepmc]
- Overview and findings from the rush Memory and Aging Project. [europepmc]
- Gender, sex steroid hormones, and Alzheimer's disease. [europepmc]
- Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. [europepmc]
- Marked gender differences in progression of mild cognitive impairment over 8 years. [europepmc]
- Sex differences in the association between AD biomarkers and cognitive decline. [europepmc]
- Age, APOE and sex: Triad of risk of Alzheimer's disease. [europepmc]
- Why estrogens matter for behavior and brain health. [europepmc]
- Sex and the development of Alzheimer's disease. [europepmc]
- Neuroimmunology and neuroepigenetics in the establishment of sex differences in the brain. [europepmc]
- Connected speech and language in mild cognitive impairment and Alzheimer's disease: A review of picture description tasks. [europepmc]
- Sexual dimorphism in predisposition to Alzheimer's disease. [europepmc]
- Understanding the impact of sex and gender in Alzheimer's disease: A call to action. [europepmc]
- Sex: A Significant Risk Factor for Neurodevelopmental and Neurodegenerative Disorders. [europepmc]
- Sex differences in Alzheimer's disease and common neuropathologies of aging. [europepmc]
- The Role of Sex and Sex Hormones in Neurodegenerative Diseases. [europepmc]
- Sex and Gender Driven Modifiers of Alzheimer's: The Role for Estrogenic Control Across Age, Race, Medical, and Lifestyle Risks. [europepmc]
- GABAergic dysfunction, neural network hyperactivity and memory impairments in human aging and Alzheimer's disease. [europepmc]
- Sex Differences in Cognitive Decline Among US Adults. [europepmc]
- APOE and Alzheimer's Disease: From Lipid Transport to Physiopathology and Therapeutics. [europepmc]
- Sex and gender differences in cognitive resilience to aging and Alzheimer's disease. [europepmc]
Related